




RealRate

PHARMACEUTICAL 2017

Anthera Pharmaceuticals Inc
Rank 290 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

Anthera Pharmaceuticals Inc Rank 290 of 313

The relative strengths and weaknesses of Anthera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anthera Pharmaceuticals Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 138% points. The greatest weakness of Anthera Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 708% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,239%, being 823% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	22,708
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,624
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-261
Other Liabilities	0
Other Net Income	1,654
Property and Equipment	763
Research and Development	46,512
Revenues	145
Selling, General and Administrative Expense	11,071

Output Variable	Value in 1000 USD
Assets	23,471
Liabilities	10,624
Expenses	57,322
Stockholders Equity	12,847
Net Income	-55,523
Comprehensive Net Income	-55,523
Economic Capital Ratio	-1,239%

